L-798106

Research use only, not for human use.

L-798106 (CM9) is a selective and potent prostaglandin-like EP3 receptor antagonist that inhibits EP4, EP1, and EP2 receptors, suppresses levels of pro-inflammatory cytokines in atherosclerosis, and attenuates PGE2-induced cough.

L-798106 is potent and highly selective prostanoid EP3 receptor antagonist (Ki=0.3 nM), it also has ?micromolar activities at the EP4, EP1 and EP2 receptors with Ki values of916 nM, >5000 nM and >5000 nM, respectively.

L-798106 (200 nM) inhibits electrical field stimulation-induced contractile responses.L-798106 (10 μM) inhibits electrical field stimulation-evoked ACh release.Cell Viability Assay Cell Line:Guinea-pig vas deferens Concentration:200 nM Incubation Time:Result:Showed an apparent pA2 of 7.48±0.25.Cell Viability Assay Cell Line:Guinea-pig tracheal smooth muscle Concentration:10 μM Incubation Time:Result:Attenuated significantly the inhibitory effect of all agents tested (in % inhibition of EFS-induced release: 8-iso-PGE1 from 56.9 to 8.6; 8-iso-PGE2 from 51.6 to 9.2; PGE2 from 61.2 to 2.9; sulprostone from 55.9 to 18.8).

L-798106 (oral gavage; 50 and 100 μg/kg; once daily; 8 w) suppresses systemic insulin resistance and AT inflammation in db/db mice.Animal Model:Male db/db mice Dosage:50 and 100 μg/kg Administration:Oral gavage; 50 and 100 μg/kg; once daily; 8 weeks Result:Suppressed the increased fasting blood glucose levels in the db/db mice.Suppressed increased proinflammatory gene expressions in the adipocytes isolated from the epididymal AT of the db/db mice.

——

GPCR/G Protein

Prostaglandin Receptor

Prostaglandin Receptor

——

——

244101-02-8

536.44

C27H22BrNO4S

>98% (HPLC)

In Vitro:?DMSO : 10 mg/mL (18.64 mM; Ultrasonic )

COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1

——

(-20℃)

With Ice Pack

≥ 2 years